8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – September 21, 2006

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-3319

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Management to Present at UBS Global Life Sciences Conference

On September 21, 2006, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer and William Federici, Chief Financial Officer, will participate in the UBS Global Life Sciences Conference on September 27, 2006 at the Grand Hyatt Hotel in New York City. A copy of the presentation, updated from the presentation filed on Form 8-K on May 10, 2006, which will be used at the UBS Global Life Sciences Conference and potentially at other industry and investor presentations delivered by members of the Company’s management from time to time, is attached as Exhibit 99.1 and incorporated by reference into this Item 7.01. A copy of the press release is attached hereto as Exhibit 99.2 and also incorporated herein by reference. Playback of the UBS Global Life Sciences presentation will be available through the Investor link of the Company's website, http://www.westpharma.com through October 28, 2006.

Company Provides Additional Details of China Expansion Plans

As part of an overall effort to increase manufacturing capacity in its European and Asia Pacific operations, the Company intends to establish a manufacturing presence in the Peoples Republic of China. Management is executing plans that will culminate in a new plastic injection-molding plant, with planned completion in 2009, and the Company has entered into a joint venture with a local medical rubber manufacturer, which is designed to lead to a new rubber components plant that would come on line in 2011, subject to the transfer of manufacturing licenses and necessary government and regulatory approval. The plastics plant initially will be dedicated to supporting a customer’s requirements for co-molded infusion bottle closures for the domestic market. Acquisition of land and arrangements for the necessary utilities and improvements to support the new plants are being finalized.

The Company currently anticipates that it will invest a total of approximately $80 million in the two China plants, which be spent over the next five years.

Additional Information

The Company makes no admission as to the materiality of any information in this report. The information contained in the slides is summary information that is intended to be considered in the context of the Company’s SEC filings and other public announcements that the Company makes, by press release or otherwise, from time to time.

The information in this report (including Exhibit 99.1 and Exhibit 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statement and Exhibits

(d)	Exhibits
	Exhibit #	Description
	99.1	Investor presentation materials.
	99.2	West Pharmaceutical Services, Inc. Press Release dated September 21, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

September 26, 2006

2

EX-99

Donald E. Morel, Jr., Ph.D.

Chairman & Chief Executive Officer

William J. Federici

Vice President & Chief Financial Officer

UBS Global Life Sciences

September 27, 2006

NYSE: WST

www.westpharma.com

         Certain statements contained in this presentation and certain statements that may be made by management of the
Company orally during this presentation are forward-looking statements that set forth anticipated results based on
management’s plans and assumptions. Such statements give our current expectations or forecasts of future events – they do
not relate strictly to historical or current facts. In particular, these include statements concerning future actions, future
performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as
legal proceedings and financial results. We have tried, wherever possible, to identify such statements by using words such as
“estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms of similar meaning in connection with
any discussion of future operating or financial performance or condition.

         We cannot guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties
materialize, or if underlying assumptions are inaccurate, actual results could differ materially from past results and those
expressed or implied in any forward-looking statement.  You should bear this in mind as you consider forward-looking
statements. We cannot predict or identify all such risks and uncertainties, but factors that could cause the actual results to
differ materially from expected and historical results include the following:  sales demand; timing and commercial success of
customers’ products incorporating our products and services, including specifically, the Exubera® Inhalation-Powder insulin
device; customers’ changes to inventory requirements and manufacturing plans that alter existing orders or ordering patterns
for our products; our ability to pass raw-material cost increases on to customers through price increases; maintaining or
improving production efficiencies and overhead absorption; physical limits on manufacturing capacity that may limit our ability
to satisfy anticipated demand; the availability of labor to meet increased demand; competition from other providers; the
successful integration of acquired businesses; average profitability, or mix, of products sold in a reporting period; financial
performance of unconsolidated affiliates; strength of the U.S. dollar in relation to other currencies, particularly the Euro, UK
Pound, Danish Krone, Japanese Yen and Singapore Dollar; higher interest rates; the availability and cost of property and
casualty insurance; interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the
availability of raw materials and key bought-in components and finished products, including products produced in northern
Israel;  raw-material price escalation, particularly petroleum-based raw materials, and energy costs; and availability, and pricing
of materials that may be affected by vendor concerns with exposure to product-related liability.

         We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future
events or otherwise.   

Safe Harbor Statement

Corporate Profile

World's premier manufacturer of
components and systems for
injectable drug delivery

Stoppers and seals for vials

Disposable components
used in syringe, IV, blood
collection and diagnostic
systems

Founded in 1923

HQ in Lionville, PA

2005 sales $700M

Market capitalization $1.3 Billion

Diverse Customer Base

Company Estimated Market Share: 70% in Pharma; 70% in Device; 95% in Biotech

32 manufacturing sites

34 sales offices

7 technical centers

6,000 employees worldwide

Global Presence

Key Company Developments

Acquisition of Monarch Laboratories

Acquisition of The Tech Group

Acquisition of Medimop

Sale of GFI Clinical Unit

Sale of Contract Manufacturing Operations

New management team

Restructuring and increased CAPEX

Sale of OTC Research Services Group

Kinston plant accident

Kinston restart

2-for-1 stock split

Divestiture of Drug Delivery

FY 2005

FY 2004

FY 2003

FY 2002

FY 2001

2003-2005

Recorded Record Sales and Earnings

(in millions)

Strong Sales Growth

$224

          Acquisitions

           Core Business

$107

FY05 Net sales: Approx. $700 MM

Markets

Geographic Sales Mix(2005, based on point of sale)

Pharmaceutical Systems Competitive Edge

Unmatched experience/expertise: drug material
interface

Ability to source components from multiple
locations globally

Protected IP: West’s components and systems

Regulatory barrier to entry:  NDA and ANDA
filing must include reference to all
packaging/components in contact with the drug:

1.

West Drug Master File (DMF) 1546 is confidential

2.

West DMF includes functionality data (multi-year studies)

3.

All primary package changes require new stability/ functionality
studies for new filing

Pharmaceutical Systems Growth Strategy

Maximize the value of West’s core business

Market segmentation

Generate maximum value from key growth drivers

New product innovation

Lean manufacturing

Geographic expansion

Strategic acquisitions

Pharmaceutical Systems Capabilities

Offer elastomeric components with advanced
coatings and barrier films

Post manufacturing processes to increase efficiency
of injectable drug production

Anti-counterfeiting technologies

Contract analytical services

Plastic and glass material testing

FluroTec^® and

BarrierCoatings

Westar^®
Processing

West Spectra^TM

Biotechnology/Oncology

Reconstitution Systems

Needleless Drug

Anti- counterfeiting/product tracking

Systems and Components

Prefillable syringes

Tech Group Growth Strategy

Build market share in multi-component systems
for drug delivery

Leverage West and Tech customer base

Develop a portfolio of drug delivery systems for
injectable, transmucosal, and pulmonary delivery

Pursue selected consumer opportunities

License or acquire innovative technologies

The Tech Group Capabilities

Custom contract-manufacturing services

Precision plastic injection-molding and assembly

Expertise in product design, including in-house mold
design and construction

Automated assembly solutions

Quick-response center for developmental and
prototype tooling

Drug Delivery
Components and
Systems

Health Care and
Consumer Products

Diabetes

Components

for Pen System Applications

Components for

Traditional System
Applications

Devices

Tech Group Competitive Edge

Technical excellence

Regulatory expertise

Analytical lab services

Tooling

High volume assembly

Six Sigma support

   .12

-

-

-

-

-

Interest Payment

$1.15*

$1.40

$1.33

$1.32

   $.96

$.83

EPS Non-GAAP

-

-

(.02)

-

-

-

Affiliate Gain

-

-

    .30

(.42)

-

-

Kinston

-

-

-

-

(.03)

-

Foreign Currency

   (.02)

   .05

(.07)

-

(.09)

-

Unusual Tax
Items

-

(.04)

    .03

    .26

   .30

  .05

Restructuring

$1.05

$1.39

$1.09

$1.48

$.78

$.78

EPS Reported

1^st H 06

2005

2004

2003

2002

2001

GAAP/Non-GAAP Reconciliation

* Included in 2006 full-year non GAAP EPS guidance of $1.82- $1.88.

This information is being provided for the convenience of readers in making comparisons between the periods presented
and other periods

Second Quarter Results
($ in millions, except per share data)

$0.38

$0.62

E.P.S. from Continuing Operations

$0.37

$0.62

Non-GAAP E.P.S. from Continuing Operations

$12.2

$20.7

Income from Continuing Operations

$19.9

$32.1

Operating Profit

$31.9

$36.9

Selling, General & Administrative Expenses

    29%

29%

Gross Margin

  $173.0

$240.2

Net Sales

2005

2006

2005 E.P.S. from continuing operations includes a $0.03 charge related to the repatriation of funds
under AJCA and a $0.04 favorable impact related to the reversal of a restructuring reserve.

Capital Management

$118.8

$136.6

Working Capital

          $26.8

      YTD Spending

      Full Yr Expected - up to $95                                                     

Capital Expenditures:

45.0%

39.8%

     Debt to Total Invested Capital

$625.0

$652.7

Total Capitalization

$281.0

$259.9

Total Debt

12/31/05

6/30/06

($M)

Debt to Total Capitalization

Goal: 40-45% excluding acquisitions and significant capital expansion

Summary

West has a set of competitive advantages that uniquely
position the company for future growth

These competitive advantages capitalize on the primary
growth drivers in key market segments

Global, diverse customer base

Global manufacturing capability

Solid financial base

Strong, experienced management team focused on
execution

Strong corporate governance

Donald E. Morel, Jr., Ph.D.

Chairman & Chief Executive Officer

William J. Federici

Vice President & Chief Financial Officer

UBS Global Life Sciences

September 27, 2006

NYSE: WST

www.westpharma.com

EX-99

Contacts: West Pharmaceutical Services, Inc. Michael A. Anderson Vice President and Treasurer (610) 594-3345 Investors and Financial Media: Financial Dynamics Julie Huang / Theresa Kelleher (212) 850-5600 wst@fd.com

Exhibit 99.2

WEST PHARMACEUTICAL SERVICES TO PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE

LIONVILLE, PA, September 21, 2006 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced that Donald E. Morel, Jr., Ph.D, Chairman and Chief Executive Officer and William Federici, Chief Financial Officer, will be presenting at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York, NY. The presentation is scheduled for Wednesday, September 27 at 2:00 p.m. (EST).

A link to the audio portion of West’s presentation will be available through the Investor link of the Company’s website, www.westpharma.com.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is the world’s leading manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. West’s customers include the world’s leading pharmaceutical, biotechnology, generic drug and medical device producers. Internationally headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.